$4 Stock (Urgent Opportunity) A compound originally isolated from an Ethiopian shrub called Maytenus ovatus… Is now part of the formula of a breakthrough cancer treatment. It just recently received accelerated FDA approval. Click here for the full story (including the $4 stock behind this breakthrough). Yours in smart speculation, Ryan Fitzwater, Publisher Monument Traders Alliance P.S. We've all heard the stories of scientists discovering cancer-fighting compounds in nature... But rarely do we hear about where that research ends up. This newly-approved drug uses Maytenus ovatus to infiltrate cancer cells and destroy them from the inside. Here's why some go so far as to call it a "miracle"... - It's the first new treatment for this type of cancer since 2014...
- A significant portion of patients went into full remission...
- The drug costs 97.5% less than other next gen cancer treatments like CAR-T...
- All with far less severe side effects!
Alexander Green from The Oxford Club believes this tiny stock won't be $4 for long. Analysts agree. The average price target is $12... a triple from current prices. Guggenheim predicts it could go to $22 in as little as one year. Click here to get all the details. |
Tidak ada komentar:
Posting Komentar